Specify a stock or a cryptocurrency in the search bar to get a summary
Torii Pharmaceutical Co Ltd
4551Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc. Address: Torii Nihonbashi Bldg., Tokyo, Japan, 103-8439
Analytics
WallStreet Target Price
622 741.89 JPYP/E ratio
24.0543Dividend Yield
2.84 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4551
Dividend Analytics 4551
Dividend growth over 5 years
150 %Continuous growth
2 yearsPayout Ratio 5 years average
49 %Dividend History 4551
Stock Valuation 4551
Financials 4551
Results | 2019 | Dynamics |